RESUMO
BACKGROUND: Ascarid infections are among the most prevalent intestinal parasitic infections occurring in dogs around the world, with Toxocara canis and Toxascaris leonina commonly observed. Toxocara canis can cause considerable disease in dogs and humans, and year-round prophylactic treatment and control in dogs is recommended. Elimination of immature stages of these parasites before egg-laying will reduce environmental contamination and the risk of infection for both dogs and humans. Studies were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced immature adult (L5) and adult T. canis, and adult T. leonina infections in dogs. METHODS: Six negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated efficacy against immature adult (L5) T. canis, adult T. canis, and adult T. leonina. Sixteen to 40 dogs were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Efficacy was based on the number of worms recovered at necropsy 7-10 days after treatment compared to placebo control. RESULTS: Based on geometric mean worm counts, efficacy of the sarolaner + moxidectin + pyrantel combination was ≥ 95.2% against immature adult T. canis, ≥ 97.3% against adult T. canis, and ≥ 89.7% against adult T. leonina. There were no treatment-related adverse events in any study. CONCLUSIONS: These studies confirm the efficacy of a single dose of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against immature adult and adult T. canis, and adult T. leonina infections in dogs.
Assuntos
Antinematódeos/administração & dosagem , Infecções por Ascaridida/veterinária , Doenças do Cão/tratamento farmacológico , Enteropatias Parasitárias/veterinária , Administração Oral , Animais , Infecções por Ascaridida/tratamento farmacológico , Azetidinas/administração & dosagem , Cães , Combinação de Medicamentos , Feminino , Enteropatias Parasitárias/tratamento farmacológico , Macrolídeos/administração & dosagem , Masculino , Contagem de Ovos de Parasitas , Pirantel/administração & dosagem , Compostos de Espiro/administração & dosagem , Comprimidos , Toxascaris/efeitos dos fármacos , Toxascaris/fisiologia , Toxocara canis/efeitos dos fármacos , Toxocara canis/fisiologia , Resultado do TratamentoRESUMO
The purpose of this study was 2-fold: 1) to investigate the prevalence of gastrointestinal parasite infection in cats reared in Daegu, Republic of Korea and 2) to assess the efficacy and safety of a topical emodepside/praziquantel formulation for cats with parasitic infections. The gastrointestinal parasite infections were examined microscopically using the flotation method. Of 407 cats, 162 (39.8%) were infected by at least one gastrointestinal parasite, including Toxocara cati (63.0%), Toxascaris leonina (31.5%), Taenia taeniaeformis (3.7%), and Cystoisospora felis (1.9%). None of the infected animals had multiple infections. When the data were analyzed according to sex, age, and type of cat, stray cats showed statistically higher prevalence than companion cats (P<0.05). On the 5th day after treatment, no parasitic eggs were detected using microscopic examination. In addition, no adverse effects, such as abnormal behaviors and clinical symptoms, were observed in the cats treated with the drug. These results quantify the prevalence of gastrointestinal parasites in cats in Daegu, Republic of Korea, and show that topical emodepside/praziquantel is a safe and effective choice for treating the parasitic infections in cats.
Assuntos
Anti-Helmínticos/administração & dosagem , Doenças do Gato/tratamento farmacológico , Depsipeptídeos/administração & dosagem , Trato Gastrointestinal/parasitologia , Enteropatias Parasitárias/veterinária , Praziquantel/administração & dosagem , Animais , Doenças do Gato/parasitologia , Gatos , Composição de Medicamentos , Quimioterapia Combinada , Feminino , Enteropatias Parasitárias/tratamento farmacológico , Enteropatias Parasitárias/parasitologia , Masculino , República da Coreia , Taenia/efeitos dos fármacos , Taenia/isolamento & purificação , Taenia/fisiologia , Toxascaris/efeitos dos fármacos , Toxascaris/isolamento & purificação , Toxascaris/fisiologia , Toxocara/efeitos dos fármacos , Toxocara/isolamento & purificação , Toxocara/fisiologiaRESUMO
The efficacy of a novel topical fipronil, (S)-methoprene, eprinomectin and praziquantel combination product (BROADLINE(®), Merial) was evaluated against adult Toxascaris leonina ascarids in experimentally infected cats in two controlled studies under an identical protocol. For each study, 30 nematode-naive, purpose-bred European Short Hair cats were inoculated orally with approximately 300 larvated T. leonina eggs. Twenty-two and 24 cats, respectively, that were shown to be positive for Toxascaris eggs by pre-treatment faecal examination were subsequently included in the two studies. In each study, the animals were allocated randomly to an untreated (control) group or to a treatment group. The treatment was a novel topical combination: fipronil (8.3%, w/v), (S)-methoprene (10%, w/v), eprinomectin (0.4% w/v) and praziquantel (8.3% w/v). Treatment was applied on Day 0 at 0.12 mL/kg bodyweight. For parasite recovery and count, cats were euthanized humanely seven days after treatment and necropsied. All untreated cats harboured adult T. leonina (range, 1-31 nematodes). The treatment provided a high level of efficacy against adult T. leonina in both studies (95.8% and 98.1%, respectively p<0.001). All cats accepted the treatment well based on hourly post-treatment observations for 4h and daily observations thereafter. No adverse experiences or other health problems were observed throughout the studies. Thus the data indicate that this novel combination product will provide a safe and effective treatment against T. leonina in cats.
Assuntos
Antiparasitários/administração & dosagem , Doenças do Gato/tratamento farmacológico , Toxascaríase/veterinária , Animais , Gatos , Combinação de Medicamentos , Feminino , Ivermectina/administração & dosagem , Ivermectina/análogos & derivados , Masculino , Metoprene/administração & dosagem , Praziquantel/administração & dosagem , Pirazóis/administração & dosagem , Distribuição Aleatória , Toxascaríase/tratamento farmacológico , Toxascaris/fisiologia , Resultado do TratamentoRESUMO
The migration of larvae of Toxascaris leonina was studied in 168 white mice. The larvae were found in lungs of 96% of infected mice on days 4-135, in genital organs (84%), intestinal mucosa (81%) and skeletal muscles (100%) on day 10 post infection. The maximum number of larvae were detected in intercostal muscles on day 105 post infection.